Sumitomo Dainippon Pharma Co ( (JP:4506) ) has issued an update.
Sumitomo Pharma has revised its financial forecasts for the fiscal year ending March 31, 2025, showing an increase in expected revenue and profits due to higher-than-anticipated sales in North America. Additionally, the company recorded significant gains from the transfer of equity interests in its regenerative medicine and cell therapy business, which positively impacts its financial results.
More about Sumitomo Dainippon Pharma Co
Sumitomo Pharma Co., Ltd. is a Japanese company headquartered in Osaka, operating in the pharmaceutical industry. The company focuses on developing and marketing therapeutic products, with a notable presence in the North American market, particularly with products like ORGOVYX for advanced prostate cancer.
YTD Price Performance: 15.33%
Average Trading Volume: 481
Technical Sentiment Signal: Buy
Current Market Cap: $1.88B
Learn more about 4506 stock on TipRanks’ Stock Analysis page.